Grant of Restricted Stock Units and Warrants to Employees in Genmab

[ad_1] Company Announcement COPENHAGEN, Denmark; September 28, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 7,609 restricted stock units and 7,873 warrants to employees…

Genmab to Present at Morgan Stanley 21st Annual Global Healthcare Conference

[ad_1] Media Release COPENHAGEN, Denmark; August 28, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan van de Winkel, Ph.D. and Chief Financial Officer Anthony Pagano…

Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen

[ad_1] Company Announcement COPENHAGEN, Denmark; April 24, 2023 – Genmab A/S (Nasdaq: GMAB) announced today its decision to file a request for review of the award dismissing its claims in…

Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen

[ad_1] Company Announcement COPENHAGEN, Denmark; April 21, 2023 – Genmab A/S (Nasdaq: GMAB) announced today an award in the second arbitration arising under its license agreement with Janssen Biotech, Inc.…

Completion of share buy-back program

[ad_1] Company Announcement COPENHAGEN, Denmark; April 3, 2023 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on March 31, 2023. On February 22, 2023,…

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

[ad_1] Company Announcement COPENHAGEN, Denmark; March 29, 2023 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on March 29, 2023, the Company’s Board of Directors met…

Transactions in connection with share buy-back program

[ad_1] Company Announcement COPENHAGEN, Denmark; March 13, 2023 – Genmab A/S (Nasdaq: GMAB). On February 22, 2023, Genmab announced the initiation of a share buy-back program to honor our commitments…